Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDK378 versus chemotherapy in previously treated ALK-positive advanced NSCLC
NL-OMON47784Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Feb 2014; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47784.